Bevko Bone & Minerals Complete - 240 Tablets

240 Tablets ...Read more
$34.00 each
( 0 )


+

240 Tablets

Product Description:

Bevko’s Bone & Minerals Complete contains all of the minerals needed for bone formation, plus other cofactors (such as vitamins K and D) needed to help the body absorb and use the minerals. All of the minerals in this formula are chelated with (attached to) amino acids or Krebs cycle intermediates (glycinates, aspartate, citrate, and so on) to make the minerals highly absorbable. Absorbability (or bioavailability) is crucial because a nutrient that is not absorbable cannot be used by the body, no matter how much of the nutrient you take in.

Suggested Use: As a dietary supplement, adults take 4 or more daily as directed by your physician or health-care provider.

WARNING: As with all potassium-containing supplements, persons with renal insufficiency should consult their health-care professional before using.

Why Are Minerals So Important?

Everyone (men, women, and children) needs minerals. Most people think minerals are just for bones and that calcium is the only one that is important. That statement could not be further from the truth! Minerals affect thousands of chemical reactions in your body! Every time you use a muscle, every time your heart beats, every time you breathe -- minerals are being used. For example, magnesium blocks calcium from entering the cells of the heart and smooth muscles. As a result, this mineral:

  • helps lower blood pressure
  • reduces vascular resistance
  • enables the heart to function more efficiently

Magnesium is also important to such functions as energy production, replication of cells, and enzymatic reactions in the body. ¹ (See also Cal-Mag Plus)

Isn’t Calcium All I Need for Bones?

To build bone, you need much more than calcium! Bone building requires a whole list of nutrients. For instance, if you take in just calcium and not enough (or any) magnesium, the body will waste calcium to hold on to the magnesium! Bone formation requires many nutrients, including magnesium, vitamin K, vitamin D, manganese, boron, zinc, silicon, and calcium. Bevko’s Bone & Minerals Complete contains all of these nutrients, plus extra minerals (including chromium and selenium, which are also important in many activities in the body.) All of these vitamins and minerals, plus other essential nutrients, are included in Bevko’s Bone & Minerals Complete formula.*

For details on how minerals work in the body (or what happens when you are deficient in these minerals), read the blog post "Bone & Minerals Complete"

¹ Murray, Michael T., ND; Encyclopedia of Nutritional Supplements, Prima Health (division of Prima Publishing), Rocklin, CA. 1996. pp. 161-162.

------

This product is free of corn, wheat, gluten, sugar, yeast, soy derivatives, fish, dairy peanuts, tree nuts, artificial coloring, preservatives or flavorings.

Chromemate® brand is a registered trademark of InterHealth Co.
U.S. Patent Number 4.923.855.

Chelazome® is a registered trademark of Albion® Inc.

------

References

REFERENCES FOR MAGNESIUM, CHROMIUM AND SELENIUM

1. Lindberg JS, et al., Magnesium bioavailability from magnesium citrate and magnesium oxide.J m Coll Nutr 9, 48-55, 1990.
2. Bohmer T, et al., Bioavailability of oral magnesium supplementation in female students evaluated from elimination of magnesium in 24-hour urine.Magnes Trace Elem 9, 272-278, 1990.
3. Gullestad L, et al., Oral versus intravenous magnesium supplementation in patients with magnesium deficiency.Magnes Trace Elem 10, 11-16, 1991.

4.Skobeloff EM, et al., Intravenous magnesium sulfate for the treatment of acute asthma in the emergency department.JAMA 262, 1210-1213, 1989.5.Okayama H, et al., Bronchodilating effect of intravenous magnesium sulfate in bronchial asthma.JAMA 257, 1076-1078, 1987.6.Noppen M, et al., Bronchodilating effect of intravenous magnesium sulfate in acute severe bronchial asthma.Chest 97, 373-376, 1990.7.Skorodin MS, et al., Magnesium sulfate in exacerbations of chronic obstructive pulmonary disease.Arch Intern Med 155, 496-500, 1995.8.McLean RM, Magnesium and its therapeutic uses: A review.Am J Med 96, 63-76, 1994.9.Altura BM, Basic biochemistry and physiology of magnesium: A brief review.Magnes Trace Elem 10, 167-171, 1991.10.Purvis JR and Movahed A, Magnesium disorders and cardiovascular disease.Clin Cardiol 15, 556-568, 1992.11.Altura BM, Ischemic heart disease and magnesium.Magnesium 7, 57-67, 1988.12.Hampton EM, Whang DD, and Whang R, Intravenous magnesium therapy in acute myocardial infarction.Ann Pharmacother 28, 212-219, 1994.13.Teo KK and Yusuf S, Role of magnesium in reducing mortality in acute myocardial infarction.A review of the evidence.Drugs 46, 347-359, 1993.14.Schecter M, Kaplinsky E, and Rabinowitz B, The rationale of magnesium supplementation in acute myocardial infarction.A review of the literature.Arch Intern Med 152, 2189-2196, 1992.15.Turlapaty PDMV and Altura BM, Magnesium deficiency produces spasms of coronary arteries: Relationship to etiology of sudden death ischemic heart disease.Science 208, 199,200, 1980.16.Goto K, et al., Magnesium deficiency detected by intravenous loading test in variant angina pectoris.Am J Cardiol 65, 709-712, 1990.17.Brodsky MA, et al., Magnesium therapy in new-onset atrial fibrillation.Am J Cardiol 73, 1227-1229, 1994.18.Perticone F, et al., Antiarrhythmic short-term protective magnesium treatment in ischemic dilated cardiomyopathy.J Am Coll Nutr 9, 492-499, 1990.19.Gottlieb SS, et al., Prognostic importance of serum magnesium concentration in patients with congestive heart failure.J Am Coll Cardiol 16, 827-831, 1990.20.Gottlieb SS, Importance of magnesium in congestive heart failure.Am J Cardiol 63, 39G-42G, 1989.21.Whelton PK and Klag, Magnesium and blood pressure: Review of the epidemiologic and clinical trial experience.Am J Cardiol 63, 26G-30G, 1989.22.Joffres MR, Reed DM, and Yano K, Relationship of magnesium intake and other dietary factors to blood pressure: The Honolulu Heart Study.Am J Clin Nutr 45, 469-475, 1987.23.Witteman JCM, et al., Reduction of blood pressure with oral magnesium supplementation in women with mild to moderate hypertension.Am J Clin Nutr 60, 129-135, 1994.24.Motoyama T, Sano H, and Fukuzaki H, Oral magnesium supplementation in patients with essential hypertension.Hypertension 13, 227-232, 1989.25.Howard JMH, Magnesium deficiency in peripheral vascular disease.J Nutr Med 1, 39-49, 1990.26.Davis WH, et al., Monotherapy with magnesium increases abnormally low high density lipoprotein cholesterol: A clinical essay.Clin Ther Res 36, 341-346, 1984.27.Galland LD, Baker SM, and McLellan RK, Magnesium deficiency in the pathogenesis of mitral valve prolapse.Magnesium 5, 165-174, 1986.28.Fernandes JS, et al., Therapeutic effect of a magnesium salt in patients suffering from mitral valvular prolapse and latent tetany.Magnesium 4, 283-289, 1985.29.Altura BT and Altura BM, The role of magnesium in etiology of strokes and cerebrovasospasm.Magnesium 1, 277-291, 1982.30.Paolisso G, Sgambato S, Gambardella A, et al., Daily magnesium supplements improve glucose handling in elderly subjects.Am J Clin Nutr 55, 1161-1167, 1992.31.White JR and Campbell RK, Magnesium and diabetes: A review.Ann Pharmacother 27, 775-780, 1993.32.Djurhuus MS, et al., Insulin increases renal magnesium excretion: A possible cause of magnesium depletion in hyperinsulinaemic states.Diabetic Med 12, 664-669, 1995.33.Consensus Statement, Magnesium supplementation in the treatment of diabetes.Diabetes Care 19 (Suppl. 1), S93-S95, 1996.34.Clauw DJ, et al., Magnesium deficiency in the eosinophilia-myalgia syndrome.Arth Rheum 9, 1331-1334, 1994.35.Cox IM, Campbell MJ and Dowson D, Red blood cell magnesium and chronic fatigue syndrome.Lancet 337, 757-760, 1991.36.Ahlborg H, Ekelund LG, and Nilsson CG, Effect of potassium-magnesium aspartate on the capacity for prolonged exercise in man.Acta Physiologica Scand 74, 238-245, 1968.37.Hicks JT, Treatment of fatigue in general practice: A double blind study.Clin Med Jan, 85-90, 1964.38.Friedlander HS, Fatigue as a presenting symptom: Management in general practice.Curr Ther Res 4, 441-449, 1962.39.Shaw DL, Management of fatigue: A physiologic approach.Am J Med Sci 243, 758-769, 1962.40.Abraham G, Management of fibromyalgia: Rationale for the use of magnesium and malic acid.J Nutr Med 3, 49-59, 1992.41.Gaspar AZ, Gasser P, and Flammer J, The influence of magnesium on visual field and peripheral vasospasm in glaucoma.Opthalmologica 209, 11-13, 1995.42.Attias J, et al., Oral magnesium intake reduces permanent hearing loss induced by noise exposure.Am J Otolaryngol 15, 26-32, 1994.43.Johansson G, Backman U, Danielson B, et al., Biochemical and clinical effects of the prophylactic treatment of renal calcium stones with magnesium hydroxide.J Urol 124, 770-774, 1980.44.Wunderlich W, Aspects of the influence of magnesium ions on the formation of calcium oxalate.Urol Res 9, 157-160, 1981.45.Hallson P, Rose G, and Sulaiman, Magnesium reduces calcium oxalate crystal formation in human whole urine.Clin Sci 62, 17-19, 1982.46.Johansson G, Backman U, Danielson B, et al., Magnesium metabolism in renal stone formers.Effects of therapy with magnesium hydroxide.Scand J Urol Nephrol 53, 125-130, 1980.47.Prien E and Gershoff S, Magnesium oxide-pyridoxine therapy for recurrent calcium oxalate calculi.J Urol 112, 509-512, 1974.48.Gershoff S and Prien E, Effect of daily MgO and Vitamin B6 administration to patients with recurring calcium oxalate stones.Am J Clin Nutr 20, 393-399, 1967.49.Pak CYC and Fuller C, Idiopathic hypocitraturic calcium-oxalate nephrolithiasis successfully treated with potassium citrate.Annals Int Med 104, 33-37, 1986.50.Pak CYC, et al., Long-term treatment of calcium nephrolithiasis with potassium citrate.J Urol 134, 11-19, 1985.51.Swanson DR, Migraine and magnesium: Eleven neglected connections.Perspect Biol Med 31, 526-557, 1988.52.Ramadan NM, et al., Low brain magnesium in migraine.Headache 29, 590-593, 1989.53.Gallai V, et al., Magnesium content of mononuclear blood cells in migraine patients.Headache 34, 160-165, 1994.54.Cohen L and Kitzes R, Infrared spectroscopy and magnesium content of bone mineral in osteoporotic women.Isr J Med Sci 17, 1123-1125, 1981.55.Rude RK, Adams JS, Ryzen E, et al., Low serum concentration of 1,25-dihydroxyvitamin D in human magnesium deficiency.J Clin Endo Metabol 61, 933-940, 1985.56.Altura BM, et al., Magnesium deficiency-induced spasm of umbilical vessels: Relation to preeclampsia, hypertension, growth retardation.Science 221, 376-378, 1983.57.Conradt A, Weidinger H, and Algayer H, ON: The role of magnesium in fetal hypertrophy, pregnancy-induced hypertension, and preeclampsia.Mag Bull 6, 68-76, 1984.58.Kiss V, et al., Effect of maternal magnesium supply on spontaneous abortion and premature birth and on intrauterine fetal development: Experimental epidemiological study.Mag Bull 3, 73-79, 1981.59.Spatling L and Spatling G, Magnesium supplementation in pregnancy.A double-blind study.Br J Obstet Gynaecol 95, 120-125, 1988.60.Rudnicki M, et al., The effect of magnesium on maternal blood pressure in pregnancy-induced hypertension.A randomized double-blind placebo-controlled trial.Acta Obstet Gynecol Scand 70, 445-450, 1991.61.Martin RW and Morrison JC, Oral magnesium for tocolysis.Contemp Ob/Gyn 30, 111-118, 1987.62.Sibai BM, et al., Magnesium supplementation during pregnancy: A double-blind randomized controlled clinical trial.Am J Obstet Gynecol 161, 115-119, 1989.63.Abraham GE, Nutritional factors in the etiology of the premenstrual tension syndromes.J Repro Med 28, 446-464, 1983.64.Piesse JW, Nutritional factors in the premenstrual syndrome.Int Clin Nutr Rev 4, 54-81, 1984.65.Rosenstein DL, et al., Magnesium measures across the menstrual cycle in premenstrual syndrome.Biol Psychiatr 35, 557-561, 1994.66.Facchinetti F, et al., Oral magnesium successfully relieves premenstrual mood changes.Obstet Gynecol 78, 177-181, 1991.67.Goei GS and Abraham GE, Effect of nutritional supplement, Optivite, on symptoms of premenstrual tension.J Repro Med 58, 527-531, 1983.68.Majumdar P and Boylan M, Alteration of tissue magnesium levels in rats by dietary vitamin B6 supplementation.Int J Vit Ntr Res 59, 300-303, 1989.69.Seelig MS, Magnesium deficiency with phosphate and vitamin D excess: Role in pediatric cardiovascular nutrition.Cardio Med 3, 637-650, 1978.Chromium1.Mertz W, Chromium in human nutrition: A review.J Nutr 123, 626-633, 1993.2.Evans GW, Chromium picolinate is an efficacious and safe supplement.Int J Sport Nutr 3, 117-122, 1993.3.Abraham AS, Brooks BA, and Eylath U, The effects of chromium supplementation on serum glucose and lipids in patients with and without non-insulin dependent diabetes.Metabolism 41, 768-771, 1992.4.Mossop RT, Effects of chromium (III) on fasting blood glucose, cholesterol, and cholesterol HDL levels in diabetics.Centr Afr J Med 29, 80-82, 1983.5.Rabinowitz MB, et al., Effect of chromium and yeast supplements on carbohydrate metabolism in diabetic men.Diabetes Care 6, 319-327, 1983.6.Anderson RA, Chromium, glucose tolerance, and diabetes.Biological Trace Element Research 32, 19-24, 1992.7.Anderson RA, et al., Effects of supplemental chromium on patients with symptoms of reactive hypoglycemia.Metabolism 36, 351-355, 1987.8.Lee NA and ReasnerCA, Beneficial effect of chromium supplementation on serum triglyceride levels in NIDDM.Diabetes Care 17, 1449-1452, 1994.9.Offenbach E and Pistunyer F, Beneficial effect of chromium-rich yeast on glucose tolerance and blood lipids in elderly patients.Diabetes 29, 919-925, 1980.10.Press RI, Geller J, and Evans GW, The effect of chromium picolinate on serum cholesterole and apolipoprotein fractions in human subjects.Western J Med 152, 41-45, 1993.11.Wang NM, et al., Serum cholesterol of adults supplemented with brewer’s yeast or chromium chloride.Nutr Res 9, 989-998, 1989.12.Roeback JR, et al., Effects of chromium supplementation on serum high-density lipoprotein cholesterol levels in men taking beta-blockers.Annals Int Med 115, 917-924, 1991.13.Lefavi RG, et al., Lipid-lowering effect of a dietary chromium (III) nicotinic acid complex in male athletes.Nutr Res 13, 239-249, 1993.14.McCarthy MF, Hypothesis: Sensitization of insulin-dependent hypothalamic glucoreceptors may account for the fat-reducing effects of chromium picolinate.J Optimal Nutr 21, 36-53, 1993.15.Evans GW and Pouchnik DJ, Composition and biological activity of chromium-pyridine carbosylate complexes.J Inorganic Biochemistry 49, 177-187, 1993.16.Katts GR, Ficher JA, and Blum K, The effects of chromium picolinate supplementation on body composition in different age groups.Age 14, 138(Abstract #40), 1991.17.Abdel KM, et al., Glucose tolerance in blood and skin of patients with acne vulgaris.Ind J Derm 22, 139-149, 1977.18.Cohen J and Cohen A, Pustular acne staphyloderma and its treatment with tolbutamide.Can Med Assoc J 80, 629-632, 1959.19.McCarthy M, High chromium yeast for acne?Med Hypoth 14, 307-310, 1984.20.Schrauzer GN, Shrestha KP, and Flores MP, Somatopsychological effects of chromium supplementation.J Nutr Med 3, 43-48, 1992.21.Seaborn C and Stoecker B, Effects of antacid or ascorbic acid on tissue accumulation and urinary excretion of chromium.Nutr Res 10, 1401-1407, 1990.22. Preuss HG. Bagchi D. Bagchi M. Rao CV. Dey DK. Satyanarayana S. Effects of a natural extract of (-)-hydroxycitric acid (HCA-SX) and a combination of HCA-SX plus niacin-bound chromium and Gymnema sylvestre extract on weight loss. [Clinical Trial. Journal Article. Randomized Controlled Trial] Diabetes, Obesity & Metabolism. 6(3):171-80, 2004 May. 23. Sun C. Wang S. Xia W. Sun W. [Effects of chromium and fish oil on blood lipid and blood glucose in obese rats]. [Chinese] [Journal Article] Wei Sheng Yen Chiu/Journal of Hygiene Research. 32(2):110-2, 2003 Mar.24. Kleefstra N. Bilo HJ. Bakker SJ. Houweling ST. [Chromium and insulin resistance]. [Review] [18 refs] [Dutch] [Journal Article. Review. Review, Tutorial] Nederlands Tijdschrift voor Geneeskunde. 148(5):217-20, 2004 Jan 31.25. Franklin M. Odontiadis J. Effects of treatment with chromium picolinate on peripheral amino acid availability and brain monoamine function in the rat. [Journal Article] Pharmacopsychiatry. 36(5):176-80, 2003 Sep.26. Liu J. Zhu Z. Hua R. Liu X. Liu X. [Determination of trace elements Fe, Cr, Co and Ni in serum of middle-aged and aged people with slight and severe diabetes]. [Chinese] [Journal Article] Guang Pu Xue Yu Guang Pu Fen Xi/Spectroscopy & Spectral Analysis. 20(1):87-8, 2000 Feb. 27. Keszthelyi Z. Past T. Koltai K. Szabo L. Mozsik G. [Chromium (III)-ion enhances the utilization of glucose in type-2 diabetes mellitus]. [Hungarian] [Case Reports. Clinical Trial. Journal Article] Orvosi Hetilap. 144(42):2073-6, 2003 Oct 19.


Selenium1.Fan AM and Kizer KW, Selenium: Nutritional, toxicological, and clinical aspects.West J Med 153, 160-167, 1990.2.Burk RF, Recent developments in trace element metabolism and function:Newer roles of selenium in nutrition.J Nutr 119, 1051-1054, 1989.3.Contempre B, et al., Effect of selenium supplementation on thyroid hormone metabolism in an iodine and selenium deficient population.Clin Endocrinol 36, 579-583, 1992.4.Anderson O and Nielsen JB, Effects of simultaneous low-level dietary supplementation with inorganic and organic selenium on whole-body, blood, and organ levels of toxic metals in mice.Environ Health Perspect 102 (Suppl. 3), 321-324, 1994.5.Thomson CD, et al., Effect of prolonged supplementation with daily supplements of selenomethionine and sodium selenite on glutathione peroxidase activity in blood of New Zealand residents.Am J Clin Nutr 36, 24-31, 1982.6.Lavender OA, et al., Bioavailability of selenium to Finnish men as assessed by platelet glutathione peroxidase activity and other blood parameters.Am J Clin Med 37, 887-897, 1983.7.Mutanen M, Bioavailability of selenium.Annals Clin Res 18, 48-54, 1986.8.National Research Council, Diet and Health.Implications for Reducing Chronic Disease Risk.National Academy Press, Washington, DC, 1989, pp.376-379.9.Hocman G, Chemoprevention of cancer: Selenium.Int J Biochem 20, 123-132, 1988.10.Wasowicz W, Selenium concentration and glutathione peroxidase activity in blood of children with cancer.J Trace Elem Electrolytes Health Dis 8, 53-57, 1994.11.Fex G, Petterson B, and Akesson B, Low plasma selenium as a risk factor for cancer death in middle-age men.Nutr Cancer 10, 221-229, 1987.12.Kok FJ, et al., Is serum selenium a risk factor for cancer in men only?Am J Epidemiol 125, 12-16, 1987.13.Kiremidjian-Schumacher L and Stotsky G, Selenium and immune responses.Environmental Res 42, 277-303, 1987.14.Kiremidjian-Schumacher L, et al., Supplementation with selenium and human immune cell functions; II, Effect on cytotoxic lymphocytes and natural killer cells.Biol Trace Elem Res 41, 115-127, 1994.15.Roy M, Supplementation with selenium and human immune cell functions; I, Effect on lymphocyte proliferation and interleukin 2 receptor expression.Biol Trace Elem Res 41, 103-114, 1994.16.Kok FJ, et al., Decreased selenium levels in acute myocardial infarction.JAMA 261, 1161-1164, 1989.17.Salonen JT, Association between cardiovascular death and myocardial infarction and serum selenium in a matched-pair longitudinal study.Lancet 2, 175-179, 1982.18.Beaglehole R, et al., Decreased blood selenium and risk of myocardial infarction.Int J Epid 19, 918-922, 1990.19.Luoma PV, et al., Serum selenium, glutathione peroxidase activity and high-density lipoprotein cholesterol – effect of selenium supplementation.Res Commun Chem Pathol Pharmacol 46, 469-472, 1984.20.Stead NW, et al., Selenium (Se) balance in the dependent elderly.Am J Clin Nutr 39, 677, 1984.21.Korpela H, et al., Effect of selenium supplementation after acute myocardial infarction.Res Commun Chem Pathol Pharmacol 65, 249-252, 1989.22.Tarp U, et al., Low selenium level in severe rheumatoid arthritis.Scand J Rheumatol 14, 97-101, 1985.23.Hinks LJ, et al., Trace element status in eczema and psoriasis.Clin Exp Derm 12, 93-97, 1987.24.Tarp U, et al., Selenium treatment in rheumatoid arthritis.Scand J Rheumatol 14, 364-368, 1985.25.Munthe E and Aseth J, Treatment of rheumatoid arthritis with selenium and vitamin E.Scand J Rheumatol 53 (Suppl.), 103, 1984.26.Swanson A and Truesdale A, Elemental analysis in normal and cataractous human lens tissue.Biochem Biophys Res Comm 45, 1488-1496, 1971.27,Karakucuk S, et al., Selenium concentrations in serum, lens, and aqueous humour of patients with senile cataract.Arch Opthalmol Scand 73, 329-332, 1995.28.Karunanithy R, Roy AC, and Ratnam SS, Selenium status in pregnancy: Studies in amniotic fluid from normal pregnant women.Gynecol Obstet Invest 27, 148-150, 1989.29.Lockitch G, et al., Selenium deficiency in low birth weight neonates: An unrecognized problem.J Pediatr 114, 865-870, 1989.30.McGlashan ND, Low selenium status and cot deaths.Med Hypothesis 35, 311-314, 1991.31.Kariks J, Cardiac lesions in sudden infant death syndrome.Forensic Sci Int 39, 211-215, 1988.32.Money DFL, Vitamin E and selenium deficiencies and their possible aetological role in the sudden infant death syndrome.NZ Med J 71, 32-34, 1970.33.Lemke R, Schafer A, and Makropoulos W, Postmortem serum selenium concentrations and their possible etiological role in sudden infant death (SID). Forensic Sci Int 60, 179-182, 1993.34.Centers for Disease Control, Selenium intoxication.MMWR 33, 157, 1984.

Vote: ( 0 )

Give your opinion about this item:

Username:
E-mail:
List of the comments:
No comments have been posted yet.
Supplement Facts
Serving Size: 3
Servings Per Container: 80
 
  Amount Per Serving % Daily Value
Vitamin D (as cholecalciferol 800 UI 200%
Vitamin K (as phytonadione) 500 mcg 625%
Iodine (From Potassium Iodide) 120 mcg 80%
Magnesium (as magnesium aspartate 275 mcg 69%
Calcium (as 50% calcium citrate & 50% di-calcium malate) 500 mg 50%
Zinc (as Chelazome)(amino acid chelate 25 mg 167%
Manganese (as Chelazome aa chelate) 10 mg 500%
Chromium (as Chromate as polynicotinate) 300 mcg 250%
Selenium (as selenium amino acid chelate 300 mcg 429%
Molybenum (as molybenum chelazome aa chelate) 100 mcg 133%
Potassium (as potassium proteinate) 90 mcg 3%
Boron (as boron proteinate 5 mcg *
Vanadium (as vanadyl sulfate) 100 mcg *
Silica (as horsetail silica powder 10mg *
 
*Daily value not established.
 

Notes:

Other Ingrediants: sodium carboxymethycellulose, cellulose, magnesium stearate, glaze. This product is free of corn, wheat, gluten, sugar, yeast, soy derivatives, fish, dairy, peanuts, tree nuts, artificial coloring, preservatives or flavorings.

KEEP OUT OF REACH OF CHILDREN.

KEEP CONTAINER TIGHTLY CLOSED.

Tamper resistant package, do not use if seal is missing.

For optimal storage conditions, store in a cool, dry place.

(59°-77° F / 15°-25° C) (35-65% relative humidity)


Disclaimer:

*This statement has not been evaluated by the FDA.
This product is not intended to diagnose, treat, cure or prevent any disease.